Friday, March 5, 2021

China buys millions of German-made BioNTech vaccine doses

China's own Covid-19 vaccines have yet to receive public use approval from drug regulators.

Other News

Pengerusi BN terus gesa sidang Parlimen ketika darurat

BN menganggap kenyataan Menteri Di Jabatan Perdana Menteri Takiyuddin Hassan semalam mencabar kuasa Agong.

PN masih utuh, kata Bersatu

Bersatu menyatakan penghargaan kepada semua parti komponen Perikatan Nasional yang masih setia dengan gabungan itu.

Bersatu says PN still in charge, views Umno decision seriously

The party says its focus is on the economy and the pandemic, and that it takes a serious view of Umno's decision.

Hanya MySejahtera digunapakai bagi solat Jumaat di Selangor berkuat kuasa esok

Sebarang aplikasi pengimbas selain MySejahtera tidak diterima oleh Jais bagi jemaah yang ingin masuk ke dalam masjid dan surau.

BN chief Zahid repeats call for Dewan Rakyat sitting during emergency

The BN chairman also hits out at PAS' Takiyuddin Hassan for ruling out any parliamentary sitting during the virus emergency.

BioNTech’s Chinese partner Shanghai Fosun Pharmaceutical Group plans to import 7.2 million doses of the German company’s Covid-19 vaccine in the first half of 2021, Caixin news agency has learned.

Fosun is arranging logistics with several airlines to start transporting the vaccine from BioNTech’s German factory to China starting in January.

China’s own Covid-19 vaccines, developed by Sinopharm unit China National Biotec Group and CanSino Biologics, have already been administered to hundreds of thousands of people under emergency authorisation in China, but they have yet to receive public use approval from drug regulators.

In March, Fosun secured rights from BioNTech to market its vaccine across the Chinese mainland, Hong Kong, Macao and Taiwan. It said in August it intends to supply 10 million doses for Hong Kong and Macao, distributing them through Hong Kong’s Jacobson Pharma Corp.

Fosun is contracted to pay BioNTech as much as US$135 million in upfront and “potential future investment and milestone” payments for exclusive commercialisation rights in the Chinese mainland, Hong Kong, Macao and Taiwan. It will be responsible for marketing and sales costs and will get 65% of gross profits.

Fosun is also responsible for seeking approval of the vaccine from regulators in mainland China and Hong Kong. It has yet to apply for authorisation on the mainland but is getting ready to submit paperwork to drug regulators in Hong Kong, Bloomberg reported.

BioNTech has told Caixin that the vaccine intended for China will be produced at its facility in Marburg, Germany.

According to Caixin, Fosun has said that in the future it might negotiate with BioNTech the possibility of manufacturing and packaging the vaccine in China.

Follow us on Telegram for the latest updates:

Subscribe to our newsletter

To be updated with all the latest news and analyses.

Related Articles

New cases back over 2,000 but recoveries still ahead

2,063 new cases, 2,922 recoveries.

UK, others agree to fast-track adapted Covid-19 vaccines

The agreement will avert the need for lengthy clinical studies if authorised vaccines are adapted in future, as long as the manufacturers offer 'robust evidence' of their potency and safety.

Five Eyes urged to strengthen ties with Greenland to secure vital rare earths

China controls about 90% of the supply of the world’s rare earths, which are essential for many modern systems.

Washington outlines new global strategy: China looms large

State secretary Antony Blinken says on virtually every front, the US will likely have to deal with the communist government in Beijing.

Australia extends international flight ban for 3 more months

Anyone hoping to enter Australia will have longer to wait as arrivals are limited to the capacity of mandatory quarantine hotels.